Nitrosourea combinations in lung cancer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BCNU, CCNU, and methyl CCNU have undergone extensive trial in multiple drug combinations for bronchogenic carcinoma. The addition of a nitrosourea appears to be an improvement over cyclophosphamide used alone in oat cell carcinoma and over the two drug combination of cyclophosphamide and methotrexate in both adenocarcinoma of the lung and oat cell disease. Encouraging response rates have been seen in squamous lung cancer with multiple drug combinations of a nitrosourea, an alkylating agent, vincristine, and bleomycin with or without adriamycin. The nitrosoureas have been easily incorporated, at reduced doses, into multiple drug regimens with cumulative myelosuppression seen only when the interval between nitrosourea doses is < 6 weeks. Conclusions about the ultimate role of these compounds in lung cancer treatment must await comparative trials of combinations with and without a nitrosourea, and further exploration of new approaches to increase their therapeutic index.

Original languageEnglish (US)
Pages (from-to)757-760
Number of pages4
JournalCancer Treatment Reports
Volume60
Issue number6
StatePublished - 1976
Externally publishedYes

Fingerprint

Drug Combinations
Lung Neoplasms
Cyclophosphamide
Semustine
Lomustine
Carmustine
Small Cell Carcinoma
Bronchogenic Carcinoma
Alkylating Agents
Bleomycin
Vincristine
Methotrexate
Doxorubicin
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nitrosourea combinations in lung cancer. / Livingston, Robert B.

In: Cancer Treatment Reports, Vol. 60, No. 6, 1976, p. 757-760.

Research output: Contribution to journalArticle

@article{9d081d66863c421f94a579b8f096ede0,
title = "Nitrosourea combinations in lung cancer",
abstract = "BCNU, CCNU, and methyl CCNU have undergone extensive trial in multiple drug combinations for bronchogenic carcinoma. The addition of a nitrosourea appears to be an improvement over cyclophosphamide used alone in oat cell carcinoma and over the two drug combination of cyclophosphamide and methotrexate in both adenocarcinoma of the lung and oat cell disease. Encouraging response rates have been seen in squamous lung cancer with multiple drug combinations of a nitrosourea, an alkylating agent, vincristine, and bleomycin with or without adriamycin. The nitrosoureas have been easily incorporated, at reduced doses, into multiple drug regimens with cumulative myelosuppression seen only when the interval between nitrosourea doses is < 6 weeks. Conclusions about the ultimate role of these compounds in lung cancer treatment must await comparative trials of combinations with and without a nitrosourea, and further exploration of new approaches to increase their therapeutic index.",
author = "Livingston, {Robert B}",
year = "1976",
language = "English (US)",
volume = "60",
pages = "757--760",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Nitrosourea combinations in lung cancer

AU - Livingston, Robert B

PY - 1976

Y1 - 1976

N2 - BCNU, CCNU, and methyl CCNU have undergone extensive trial in multiple drug combinations for bronchogenic carcinoma. The addition of a nitrosourea appears to be an improvement over cyclophosphamide used alone in oat cell carcinoma and over the two drug combination of cyclophosphamide and methotrexate in both adenocarcinoma of the lung and oat cell disease. Encouraging response rates have been seen in squamous lung cancer with multiple drug combinations of a nitrosourea, an alkylating agent, vincristine, and bleomycin with or without adriamycin. The nitrosoureas have been easily incorporated, at reduced doses, into multiple drug regimens with cumulative myelosuppression seen only when the interval between nitrosourea doses is < 6 weeks. Conclusions about the ultimate role of these compounds in lung cancer treatment must await comparative trials of combinations with and without a nitrosourea, and further exploration of new approaches to increase their therapeutic index.

AB - BCNU, CCNU, and methyl CCNU have undergone extensive trial in multiple drug combinations for bronchogenic carcinoma. The addition of a nitrosourea appears to be an improvement over cyclophosphamide used alone in oat cell carcinoma and over the two drug combination of cyclophosphamide and methotrexate in both adenocarcinoma of the lung and oat cell disease. Encouraging response rates have been seen in squamous lung cancer with multiple drug combinations of a nitrosourea, an alkylating agent, vincristine, and bleomycin with or without adriamycin. The nitrosoureas have been easily incorporated, at reduced doses, into multiple drug regimens with cumulative myelosuppression seen only when the interval between nitrosourea doses is < 6 weeks. Conclusions about the ultimate role of these compounds in lung cancer treatment must await comparative trials of combinations with and without a nitrosourea, and further exploration of new approaches to increase their therapeutic index.

UR - http://www.scopus.com/inward/record.url?scp=0017087266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017087266&partnerID=8YFLogxK

M3 - Article

C2 - 182365

AN - SCOPUS:0017087266

VL - 60

SP - 757

EP - 760

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -